Combretastatin A1 phosphate - Mateon Therapeutics

Drug Profile

Combretastatin A1 phosphate - Mateon Therapeutics

Alternative Names: CA1; CA1P; Combrestatin A1 diphosphate; Combretastatin A1 di-phosphate; OXi 4503

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arizona State University
  • Developer Mateon Therapeutics
  • Class Antineoplastics; Combretastatins; Diphosphates; Stilbenes
  • Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Liver cancer; Liver metastases; Myelodysplastic syndromes
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in United Kingdom (IV, Infusion)
  • 03 Nov 2017 Adverse event and efficacy data from the a phase Ib/II trial in Acute myeloid leukaemia released by Mateon Therapeutics
  • 01 Aug 2017 Additional safety and efficacy data from a phase Ib trial in Acute myeloid leukaemia released by Mateon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top